Natera, Inc. (NTRA), a clinical-stage precision medicine company, and Eledon Pharmaceuticals, Inc. (ELDN), a biotechnology firm focused on immune-modulating therapies, have formed a strategic partnership. This collaboration integrates Natera’s Prospera kidney transplant assessment test into Eledon’s Phase 3 clinical trial for tegoprubart, an investigational antibody therapy aimed at preventing organ rejection.
Eledon has finalized regulatory approval for its Phase 3 kidney transplantation program, with planned trial initiation in late 2026.
Prospera Designated for Exclusive Monitoring
Per the agreement, Prospera will act as the sole donor-derived cell-free DNA (dd-cfDNA) monitoring tool for the Phase 3 study.
The trial is projected to enroll around 600 kidney transplant patients across 100+ global transplant centers.
Prospera employs a dual-measurement algorithm, analyzing both the proportion and absolute quantity of dd-cfDNA (DQS), to identify early indications of allograft dysfunction that could necessitate further clinical assessment, including biopsy.
Tegoprubart and Clinical Trial Context
Tegoprubart, a novel anti-CD40L monoclonal antibody, has shown encouraging results in prior transplant studies. Eledon is advancing the therapy to enhance graft stability while mitigating the long-term adverse effects of standard immunosuppressants like tacrolimus.
The Phase 3 trial will integrate Prospera’s molecular monitoring for the first time as a continuous surveillance method in a large therapeutic transplant study. This partnership enables the evaluation of allograft health through repeated molecular assessment alongside the assessment of an experimental immunosuppression protocol.
